CLConsumer Defensive · Household & Personal ProductsThe 21 Wall Street analysts covering Colgate-Palmolive Co. hold a median 12-month price target of $100 — +10.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 95 of 100 as at 1 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Colgate-Palmolive Co. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (97): The share count has been shrinking and the company is not leaning on new borrowing.
Growth (49): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (4): Larger than most of the companies we track — more scrutinised, less often mispriced.
The rank is the raw material. Whether the rules would actually own Colgate-Palmolive Co. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on CL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +10.7% from it.
Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 July 2026 | Barclays | Maintains | Equal-Weight | $80 → $87 |
| 16 July 2026 | JP Morgan | Maintains | Overweight | $96 → $104 |
| 16 July 2026 | UBS | Maintains | Buy | $100 → $106 |
| 14 July 2026 | Citigroup | Maintains | Buy | $105 → $110 |
| 9 July 2026 | Piper Sandler | Maintains | Overweight | $92 → $96 |
| 9 July 2026 | Piper Sandler | Maintains | Overweight | — |
| 8 July 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 11 June 2026 | Bernstein | Initiates | Market Perform | — |
| 5 May 2026 | Barclays | Maintains | Equal-Weight | — |
| 4 May 2026 | JP Morgan | Maintains | Overweight | — |
| 4 May 2026 | RBC Capital | Reiterates | Outperform | — |
| 4 May 2026 | UBS | Maintains | Buy | — |
| 23 Apr 2026 | Morgan Stanley | Maintains | Overweight | — |
| 21 Apr 2026 | Rothschild & Co | Upgrade | Buy | — |
| 21 Apr 2026 | Rothschild& Co | Upgrade | Buy | — |
| 17 Apr 2026 | JP Morgan | Maintains | Overweight | — |
| 14 Apr 2026 | Barclays | Maintains | Equal-Weight | — |
| 10 Apr 2026 | B of A Securities | Maintains | Buy | — |
| 8 Apr 2026 | Piper Sandler | Maintains | Overweight | — |
| 8 Apr 2026 | Wells Fargo | Maintains | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 22% of US stocks
Cheaper than 35% of US stocks
Cheaper than 1% of US stocks
Cheaper than 21% of US stocks
Higher than 51% of US stocks
Higher than 29% of US stocks
Higher than 76% of US stocks
Higher than 81% of US stocks
Higher than 70% of US stocks
Higher than 99% of US stocks
Higher than 98% of US stocks
Higher than 51% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CL appears on the weeks it earns a place.
The Motley Fool published an article asking whether passive-income investors should buy Colgate-Palmolive stock, characterizing the company as an excellent choice for dividend stock investors.
Why it matters — The coverage highlights Colgate-Palmolive's appeal to dividend-focused investors, which relates directly to a key part of the company's investor base.
Colgate-Palmolive reported second-quarter earnings that beat estimates, with sales rising 4.9% driven by organic sales growth and margin improvements, while Latin America led regional performance.
Why it matters — The results show that Colgate's productivity initiatives and margin gains are successfully offsetting higher brand investments, signaling operational strength for investors tracking the company's financial health.
Colgate-Palmolive reported broad-based organic sales growth, gross-margin expansion and higher advertising spending in its second-quarter 2026 results. Executives also outlined steps to improve performance in North America amid softer category trends and elevated competition.
Why it matters — The report highlights both the company's overall strengths and a specific challenge in its North American business that executives are addressing.
Colgate-Palmolive released the transcript of its Q2 2026 earnings conference call, discussing the company's second-quarter financial results.
Why it matters — Earnings call transcripts provide CL investors with direct insight into management's perspective on quarterly performance and strategic direction.
Pre-market trading for Colgate-Palmolive is up in the final session of the week, and despite some mid-week turbulence, the stock is trading roughly even with where it was at mid-day Monday.
Why it matters — CL watchers may note the stock's stability through the week's fluctuations, reflecting a steady short-term trading pattern.
The 21 Wall Street analysts covering Colgate-Palmolive Co. have a median 12-month price target of $100, with estimates ranging from $85 to $110. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 21 analysts covering Colgate-Palmolive Co., 13 rate it a Buy, 8 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Colgate-Palmolive Co. 95 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Colgate-Palmolive Co. ranks 95 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (97 of 100).
No one can know that. What the data says: the median 12-month target from 21 analysts implies +10.7% from the last close, and Ticker Nerd's factor model ranks Colgate-Palmolive Co. 95 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Colgate-Palmolive Co. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $85 to $110 over the next 12 months.
Colgate-Palmolive Co. returned +10.3% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Colgate-Palmolive Company is an American multinational consumer products company. It focuses on the production and distribution of oral care, personal care, home care, and pet nutrition products for consumers worldwide.
The most recent item we track (The Motley Fool, 1 Aug 2026): "Should Passive Income Investors Buy Colgate Palmolive Stock?". The Motley Fool published an article asking whether passive-income investors should buy Colgate-Palmolive stock, characterizing the company as an excellent choice for dividend stock investors.
Colgate-Palmolive Company is an American multinational consumer products company. It focuses on the production and distribution of oral care, personal care, home care, and pet nutrition products for consumers worldwide. In oral care, Colgate-Palmolive offers toothpaste, toothbrushes, mouthwashes, and professional dental products under well-known global brands such as Colgate, Darlie, elmex, hello, meridol, Sorriso, and Tom’s of Maine. Its personal and home care portfolio includes liquid and bar soaps, shower gels, shampoos, conditioners, deodorants, dishwashing liquids, household cleaners, fabric conditioners, and skin health products marketed under brands like Palmolive, Softsoap, Irish Spring, Speed Stick, Ajax, Fabuloso, Murphy, Protex, Sanex, Soupline, and Suavitel. Through Hill’s Science Diet and Hill’s Prescription Diet, the company provides specialized pet nutrition products distributed via pet retailers, veterinarians, and e-commerce platforms. Headquartered in New York City, Colgate-Palmolive serves more than 200 countries and territories, playing a central role in the global consumer staples sector with extensive retail, wholesale, veterinary, and online distribution networks.
CEO Mr. Noel R. Wallace · 33,600 employees · United States · https://www.colgatepalmolive.com